Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in HBIO held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Meros Investment Management, LP | 119K | $577K | -90.3% | 2.628% | 0.25% |
| 2 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 118K | $572K | -80.4% | 2.605% | 0.53% |
| 3 | Financial Connections Group, Inc. | 30 | $0 | -90.0% | 0.001% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in HBIO — a direct measure of their conviction.
Filings activity in HBIO during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new HBIO position in Q1 2026
No new institutional buyers this quarter.
Institutions that fully closed their HBIO position in Q1 2026
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 3 | 95% | 4.19% | 33.90 pp | $1M | 89% |
| Q4 2025 | 62 | +3.3% | 38.09% | +13.21 pp | $10M | +53% |
| Q3 2025 | 60 | 12% | 24.88% | 3.89 pp | $7M | 14% |
| Q2 2025 | 68 | 25% | 28.77% | 21.99 pp | $8M | 43% |
| Q1 2025 | 91 | 3.2% | 50.76% | 149.23 pp | $14M | 78% |
| Q4 2024 | 94 | +0.0% | 199.99% | +0.00 pp | $62M | 20% |
| Q3 2024 | 94 | 6.0% | 199.99% | +0.00 pp | $79M | 10.0% |
| Q2 2024 | 100 | — | 199.99% | — | $87M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying HBIO stock.
Based on Q1 2026 13F filings, institutional ownership of Harvard Bioscience, Inc. stands at 4.2%, held across 3 reporting institutions.
Meros Investment Management, LP is the largest reported institutional holder of HBIO, with approximately 118,522 shares worth $0.00B as of Q1 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of HBIO.
Our composite Smart Money Score for HBIO is 4 out of 100 (Heavy Distribution). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
0 institutions opened new positions in HBIO during Q1 2026, while 59 fully exited. 1 added to existing positions and 1 trimmed.
HBIO institutional ownership fell by 33.90 percentage points quarter-over-quarter, with a net change of -59 holders.
The top 10 institutions account for 100.0% of all reported 13F value in HBIO, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Harvard Bioscience, Inc. (HBIO) Institutional Ownership